FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol Cara Therapeutics, Inc. [CARA]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
CHALMERS DEREK T						Cara Therapeutics, Inc. [CARA]							- 1	X Dire		ctor :		10% O	wner		
(Last) (First) (Middle)					3. D	Date of Earliest Transaction (Month/Day/Year)								_	X Office below		icer (give title ow)		Other (specify below)		
C/O CARA THERAPEUTICS, INC.						09/03/2019								President & CEO							
4 STAMFORD PLAZA, 107 ELM ST, 9TH FLOOR																					
(Street)					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)							
STAMFORD CT 06902														X	, , ,						
													Form filed by More than One Reporting Person					orting			
(City)	(St	ate) (Zip)																		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day)					Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired Disposed Of (D) (Instr. 8)					d 5)			Form: (D) or I	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	v	Amount	(A) or (D) Pric		Price		Transaction(s) (Instr. 3 and 4)				(1130.4)		
Common Stock 09/03/20					2019				S ⁽¹⁾		5,000	D \$23		\$23.2	26 ⁽²⁾	943,468)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execuse (Month/Day/Year) if any		3A. Deem Execution if any (Month/Da						6. Date Exercisable a Expiration Date (Month/Day/Year)		te	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		f ; g	8. Price Derivati Security (Instr. 5)		e derivative	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Codo	v	(0)	(D)	Date	ablo	Expiration	Titlo	or Nu of	umber							

Explanation of Responses:

- 1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2019.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$23.12 to \$23.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Remarks:

/s/Darren DeStefano, Attorney- 09/05/2019 in-Fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.